Neurogen Acquires Phase II Wyeth Compound For Parkinson’s, RLS
This article was originally published in The Pink Sheet Daily
Executive Summary
Aplindore, a partial D2 dopamine receptor agonist, may provide dosing benefits and a better side effect profile over current treatments, firm says.
You may also be interested in...
Neurogen To Try Adipiplon In Crossover Study With Ambien
Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.
Neurogen To Try Adipiplon In Crossover Study With Ambien
Anxiety, schizophrenia studies also part of broad effort to develop GABA-based insomnia agent.
Neurogen Will Advance Insomnia Drug Based On Positive Top-Line Phase IIb Results
Improved specificity will make NG2-73 first-line therapy of choice for the vast majority of insomnia sufferers, Neurogen R&D chief says.